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bstract
Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or
esistant to thalidomide (employed as second line treatment) received bortezomib (1.3 mg/m2 body surface twice weekly for 2 weeks followed
y an interval of 10–12 days) without adjunct of steroids as third line therapy. Three patients died of progressive disease during the first
cycles with bortezomib. Eighteen patients received at least 2 cycles and were evaluated for response. According to EBMT criteria, two
omplete (negative immunofixation) and seven partial (reduction of M-component > 50–75%) remissions were achieved (ITT response rate
2.8%). Duration of response lasted from 2 to 14+ months. Grades 3–4 toxicities (thrombocytopenia, leucopenia, peripheral neuropathy and
asculitis) were observed in seven patients, but no patient interrupted the treatment due to side effects. We conclude that bortezomib alone may
nduce high quality responses as third line salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated
yeloma patients with progressive disease after autologous transplantation and thalidomide.
2005 Elsevier Ltd. All rights reserved.
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. Introduction
Single or tandem autologous stem cell transplantation
AuSCT) is extensively used as front-line therapy in multi-
le myeloma (MM) [1–3]. Thalidomide, in combination with
examethasone, is highly effective for patients who relapse
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after AuSCT [4–7]. Despite the initial efficacy of these thera-
pies, however, relapse is invariably the rule. A further optimal
therapeutic choice remains undefined in these patients.
Bortezomib (VELCADE, formerly PS-341, Millennium,
USA), is a novel first-class agent that inhibits the protea-
some, a multicatalytic cellular enzyme whose activity entails
several molecular mechanisms, including, in particular, the
NF-kB pathway [8]. In phase 1–2 studies [9–11], as well as
in community centers compassionate need programs [12,13],
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bortezomib was effective as single agent in 35–38% (and
up to 50%, when dexametasone was added) of patients with
advanced MM. In a recently published phase 3 trial, borte-
zomib did significantly better than dexamethasone as salvage
treatment in MM in terms of response rate, time to pro-
gression and survival benefits [14]. Currently, bortezomib,
alone or in combination with dexamethasone and doxoru-
bicin, is under investigation as first-line and maintenance
therapy, with initial trials demonstrating an overall response
rate of about 90%, a substantial proportion of complete or
near-complete remissions and the possibility of adequate col-
lections of peripheral blood stem cells [15,16].
However, in previous studies on advanced disease, the
prior regimens were highly heterogeneous, their median num-
ber ranged from 2 [14] to 6 [10], some patients received up
to 15 lines of therapy before bortezomib [10]. Therefore, in
order to obtain more careful informations about the efficacy
and tolerability of this drug in more homogeneously and
less heavily pre-treated patients, we focused on the effects
of bortezomib on a selected cohort of MM patients who had
progressive disease after previous treatments including exclu-
sively AuSCT and thalidomide.
2. Patients and methods
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with high dose cyclophosphamide plus G-CSF. Intermediate-
high doses melphalan alone or in combination with TBI
were the conditioning regimens applied. After a first relapse
following AuSCT, all patients had received thalidomide
(100–200 mg/day p.o.), alone or in combination with dex-
amethasone (40 mg/day p.o. or i.v. for 4 days every 4 weeks),
as first salvage therapy (Table 1). After thalidomide, fif-
teen patients had relapsed and six had resulted resistant to
this treatment. The majority of patients had also received
zoledronic acid (4 mg every 4 weeks), while eleven patients
had undergone local radiotherapy. In all these 21 patients,
bortezomib was homogeneously given as third line treatment
(second salvage therapy, Table 1).
Bortezomib was used on a compassionate basis, as single
agent, at the dose of 1.3 mg/m2 body surface twice weekly
for 2 weeks (1 cycle), followed by 10–12 days without treat-
ment. The dose and the intervals were modulated according
to the manufacturer instructions in the presence of relevant
toxicities. Written informed consent and approval by local
Ethical Committees were achieved in all patients.
3. Results
A total number of 71 cycles was administered (median 3,
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CWithin a multi-institutional italian series of 49 patients
ith advanced MM treated with bortezomib on a compas-
ionate basis outside of clinical trials [13], 21 subjects were
etrospectively selected for this study (males 13, females 8;
ean age 58, range 41–67; IgG 16, IgA 5; clinical stage: IIA
, IIIA 16, IIIB 1).
All patients had received AuSCT as first line treatment
Table 1). In general, they had been previously treated
ith 2–6 cycles of VAD or VAD-modified regimens as de-
ulking treatment, followed by 1–2 mobilizing therapies
able 1
reatments and results in myeloma patients receiving bortezomib as third
ine therapy after AuSCT (first line) and thalidomide (second line)
irst line therapy
Single/double AuSCT: 9/12
Conditioning regimens: Mel 100/Mel 200/Mel 140 + TBI: 7/12/2
CR/PR after AuSCT: 5/16
Duration of response (median, range): 23 months (4–41)
econd line therapy
Thalidomide alone/plus dexamethasone: 7/14
Thalidomide dose 100/200 mg/day: 10/11
PR/NR after thalidomide: 14/7
Duration of response (median, range): 9 months (0–19)
hird line chemotherapy
Bortezomib 1.3 mg/m2 d 1, 4, 8, 11
CR/PR/NR after bortezomib: 2/7/12
Duration of response (median, range): 7 months (2–14+)
uSCT: Autologous Stem Cell Transplantation; Mel 100, 200, 140: Mel-
halan 100, 200, 140 mg/m2; TBI: total body irradiation; CR: complete
emission; PR: partial remission; NR: no response.ange 0.5–8 per patient). Three patients died of progressive
isease during the first 2 cycles with bortezomib. Eighteen
atients received at least 2 cycles and were evaluated for
esponse. Relevant adverse events are reported in Table 2.
rades 3–4 WHO toxicities (thrombocytopenia, neuropa-
hy, leucopenia, leucocytoclastic vasculits diagnosed by skin
iopsy) occurred in seven patients, determining the need of
educing or temporarily stopping the treatment.
According to EBMT criteria [17], two patients achieved
omplete remission (CR) with negative immunofixation in
erum and urine, while seven patients obtained partial remis-
ions (PR) (reduction of M-component >75% in two cases,
50% in the other five patients) (Table 2). Of interest, three
esponders to bortezomib had obtained no benefit by thalido-
ide at first relapse. The remaining twelve patients had no
able 2
dverse events occurring during bortezomib therapy, according to World
ealth Organization (WHO) criteria
Grade 1 Grade 2 Grade 3 Grade 4
hrombocytopenia 6 4 2 2
eucopenia 3 3 1
nemia 1 1
atigue 2 2
ausea/vomiting 1
one pain/arthralgias 2 4
eripheral neuropathy 3 2 1
onstipation 3 2
nfectious episodes 2
iarrhoea 1 1
utaneous vasculitis 1
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response or progressive disease and interrupted the treatment
after 2–3 cycles. Overall, intention-to-treat response rate was
42.8%. Duration of response ranged form 2 to 14+ months. In
two responders, a program of unrelated, non-myeloablative
stem cell transplantation was started. In responders, the
median value of bone marrow plasma-cell infiltration reduced
from 52% (range 15–95%) to16% (range <1–25%). Respond-
ing patients also showed significant evidence of improved
hemoglobin levels, performance status, quality-of-life and
levels of normal immunoglobulins (data not shown). Borte-
zomib normalized renal function in one patient with a mod-
erate increase of serum creatinine (2.2 g/dl). At present time,
fourteen patients are alive with a median follow-up of 13
months (range 2–26 months).
4. Discussion
Knowing which strategies offer the best therapeutic
chances after initial treatments in MM patients is manda-
tory, as quality of life and survival are significantly affected
by salvage therapies. Bortezomib has been demonstrated to
be an effective option for MM patients with advanced dis-
ease [9–14]. However, available published studies included
a mixture of patients with multiple and heterogeneous previ-
ous regimens. Here, we focused on the effects of bortezomib
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[s third line treatment (second salvage therapy) in a very
omogeneous group of MM patients induced by AuSCT and
elapsed or refractory after thalidomide employed as second
ine treatment (first salvage therapy).
Our study indicates that the use of bortezomib, in this
pecific setting, is generally safe and may be effective in
relevant proportion of cases. Responses, when occur, are
ualitatively relevant, sometimes durable and may allow to
ake time for possible following additional approaches, such
s allogeneic transplantation. If the proportion of responders
n these patients may be further increased by adding dexam-
thasone to bortezomib is currently under investigation. Of
articular interest, bortezomib was effective in some patients
n whom thalidomide had failed. This confirms that the com-
ination or the use in sequence of bortezomib and thalidomide
or its less toxic and more potent derivates, such as lenalido-
ide) could be particularly useful in MM patients.
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